Free Trial

Harmony Biosciences (HRMY) Stock Price, News & Analysis

Harmony Biosciences logo
$34.19 -0.48 (-1.38%)
Closing price 08/7/2025 04:00 PM Eastern
Extended Trading
$34.19 0.00 (0.00%)
As of 08/7/2025 07:47 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Harmony Biosciences Stock (NASDAQ:HRMY)

Key Stats

Today's Range
$33.69
$34.99
50-Day Range
$31.57
$37.52
52-Week Range
$26.47
$41.61
Volume
400,855 shs
Average Volume
634,113 shs
Market Capitalization
$1.97 billion
P/E Ratio
11.03
Dividend Yield
N/A
Price Target
$51.00
Consensus Rating
Buy

Company Overview

Harmony Biosciences Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
94th Percentile Overall Score

HRMY MarketRank™: 

Harmony Biosciences scored higher than 94% of companies evaluated by MarketBeat, and ranked 62nd out of 921 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Harmony Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 8 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Harmony Biosciences has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Harmony Biosciences' stock forecast and price target.
  • Earnings Growth

    Earnings for Harmony Biosciences are expected to grow by 27.98% in the coming year, from $2.43 to $3.11 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Harmony Biosciences is 11.03, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 27.80.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Harmony Biosciences is 11.03, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 29.88.

  • Price to Earnings Growth Ratio

    Harmony Biosciences has a PEG Ratio of 0.51. PEG Ratios below 1 indicate that a company could be undervalued.

  • Price to Book Value per Share Ratio

    Harmony Biosciences has a P/B Ratio of 2.54. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    10.20% of the float of Harmony Biosciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Harmony Biosciences has a short interest ratio ("days to cover") of 6.8.
  • Change versus previous month

    Short interest in Harmony Biosciences has recently increased by 0.68%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Harmony Biosciences does not currently pay a dividend.

  • Dividend Growth

    Harmony Biosciences does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    10.20% of the float of Harmony Biosciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Harmony Biosciences has a short interest ratio ("days to cover") of 6.8.
  • Change versus previous month

    Short interest in Harmony Biosciences has recently increased by 0.68%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Harmony Biosciences has a news sentiment score of 0.84. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.39 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 15 news articles for Harmony Biosciences this week, compared to 7 articles on an average week.
  • Search Interest

    Only 11 people have searched for HRMY on MarketBeat in the last 30 days. This is a decrease of -15% compared to the previous 30 days.
  • MarketBeat Follows

    8 people have added Harmony Biosciences to their MarketBeat watchlist in the last 30 days. This is an increase of 167% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Harmony Biosciences insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    23.60% of the stock of Harmony Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    86.23% of the stock of Harmony Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Harmony Biosciences' insider trading history.
Receive HRMY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Harmony Biosciences and its competitors with MarketBeat's FREE daily newsletter.

HRMY Stock News Headlines

Altucher: Trump’s Great Gain is starting
New Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Trump’s Great Gain” has officially begun. Altucher believes select cryptos could turn $900 into $108,000 over the next 12 months — and he’s laying out the full gameplan in a new presentation.
See More Headlines

HRMY Stock Analysis - Frequently Asked Questions

Harmony Biosciences' stock was trading at $34.41 on January 1st, 2025. Since then, HRMY shares have decreased by 0.6% and is now trading at $34.19.

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) issued its quarterly earnings data on Tuesday, August, 5th. The company reported $0.68 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.78 by $0.10. Harmony Biosciences's revenue was up 16.0% on a year-over-year basis.
Read the conference call transcript
.

Harmony Biosciences (HRMY) raised $101 million in an IPO on Wednesday, August 19th 2020. The company issued 4,700,000 shares at $20.00-$23.00 per share. Goldman Sachs, Jefferies and Piper Sandler acted as the underwriters for the IPO.

Top institutional shareholders of Harmony Biosciences include Boston Partners (1.05%), Capital Management Corp VA (0.61%), Bank of New York Mellon Corp (0.47%) and Connor Clark & Lunn Investment Management Ltd. (0.43%). Insiders that own company stock include Jack Nielsen, Andreas Wicki, Sandip Kapadia, John C Jacobs, Jeffrey M Dayno and Jeffrey Dierks.
View institutional ownership trends
.

Shares of HRMY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Harmony Biosciences investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Adobe (ADBE), ServiceNow (NOW) and Arista Networks (ANET).

Company Calendar

Last Earnings
8/05/2025
Today
8/08/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:HRMY
CIK
1802665
Fax
N/A
Employees
200
Year Founded
N/A

Price Target and Rating

High Price Target
$70.00
Low Price Target
$33.00
Potential Upside/Downside
+49.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
10 Analysts

Profitability

EPS (Trailing Twelve Months)
$3.10
Trailing P/E Ratio
11.03
Forward P/E Ratio
14.07
P/E Growth
0.51
Net Income
$145.49 million
Net Margins
23.44%
Pretax Margin
29.14%
Return on Equity
26.34%
Return on Assets
17.71%

Debt

Debt-to-Equity Ratio
0.20
Current Ratio
3.84
Quick Ratio
3.63

Sales & Book Value

Annual Sales
$714.73 million
Price / Sales
2.75
Cash Flow
$2.90 per share
Price / Cash Flow
11.77
Book Value
$13.44 per share
Price / Book
2.54

Miscellaneous

Outstanding Shares
57,530,000
Free Float
43,872,000
Market Cap
$1.97 billion
Optionable
Optionable
Beta
0.84

Social Links

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

This page (NASDAQ:HRMY) was last updated on 8/8/2025 by MarketBeat.com Staff
From Our Partners